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Protocol
ABSTRACT
Introduction Delirium is a common, serious and 
potentially preventable condition with devastating 
impact on the quality of life prompting a proliferation 
of interventional trials. Core outcome sets aim to 
standardise outcome reporting by identifying outcomes 
perceived fundamental for measurement in trials of a 
speciic interest area. Our aim is to develop international 
consensus on two core outcome sets for trials of 
interventions to prevent and/or treat delirium, irrespective 
of study population. We aim to identify additional core 
outcomes speciic to the critically ill, acutely hospitalised 
patients, palliative care and older adults.
Methods and analysis We will conduct a systematic 
review of published and ongoing delirium trials (1980 
onwards) and one-on-one interviews of patients who 
have experienced delirium and family members. These 
data will inform Delphi round 1 of a two-stage consensus 
process. In round 2, we will provide participants their own 
response, summarised group responses and those of 
patient/family participants for rescoring. We will randomise 
participants to receive feedback as proportion scoring the 
outcome as critical or as group mean responses. We will 
hold a consensus meeting using nominal group technique 
to inalise outcomes for inclusion. We will repeat the Delphi 
process and consensus meeting to select measures for 
each core outcome. We will recruit 240 Delphi participants 
giving us 80% power to detect a 1.0–1.5 point (9-point 
scale) difference by feedback method between rounds. We 
will analyse differences for subsequent scores, magnitude 
of opinion change, items retained and level of agreement.
Ethics and dissemination We are obtaining research 
ethics approvals according to local governance. 
Participation will be voluntary and data deidentiied. 
Support from three international delirium organisations will 
be instrumental in dissemination and core outcome set 
uptake. We will disseminate through peer-reviewed open 
access publications and present at conferences selected 
to reach a wide range of knowledge users.
InTRoduCTIon
Delirium is a complex syndrome charac-
terised by an acute confusional state with 
rapid onset, a fluctuating course, circadian 
disturbances and reduced or increased 
motor activity, as well as changes in cognition, 
notably in the domains of attention and high-
er-level thought processing.1 2 Delirium is a 
common, serious and potentially preventable 
source of morbidity, with devastating impacts 
on the quality of life, and mortality. Delirium 
impacts all age groups, from infants to the 
very elderly. This includes patients, including 
those accessing primary care, resident in 
nursing homes,3 those receiving palliative 
care services4 and a significant number of 
hospitalised patients, including the acute and 
critically ill. Prevalence rates in hospitalised 
patients range from 25% to 80%.5–8
Delirium is not a benign, self-limiting 
condition. In addition to increased mortality, 
delirium is associated with prolonged length 
Strengths and limitations of this study
 Ź Rigorous systematic review and core outcome set 
development methods that adhere to Cochrane and 
COMET guidelines.
 Ź Engagement with survivors of delirium during 
the development of the protocol.
 Ź Support of three international Delirium Societies 
(American, Australasian and European) will facilitate 
participant recruitment, dissemination and uptake of 
our core outcome sets.
 Ź Ability to recruit and retain participants, particularly 
delirium survivors and their family members. We 
are using multimodal recruitment strategies and 
seeking advice from organisations experienced 
in recruitment and retention of patient/family 
participants.
 Ź Ability to recruit participants with broad geographical 
representation.
 Ź Inability to come to consensus on the core outcomes 
or the measures for these outcomes.
 Ź Important outcomes are identiied that are dificult 
to measure due to the absence of valid and reliable 
measures.
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of stay; higher rates of unintentional device removal; falls 
and incontinence in the elderly; significant emotional 
distress for patients, families, caregivers and health-
care professionals9–12 and escalating public healthcare 
costs.13–15 Delirium also carries long-term consequences 
including impaired physical functioning16 17 and loss of 
independence resulting in long-term care placement,5 
caregiver burden,18 19 decreased quality of life,20 cognitive 
decline and increased risk of dementia and Alzheimer’s 
disease.11
With increased recognition of delirium as a common, 
costly and potentially preventable condition associated 
with adverse outcomes, encouragingly studies exam-
ining interventions to prevent and/or treat delirium 
continue to proliferate. Currently, there is no systematic 
approach to the selection and reporting of outcomes and 
their measures in these studies resulting in reporting of 
numerous and varied study outcomes and measures for 
these outcomes. This hinders progress towards improve-
ments in care, as to best inform the evidence base, 
outcomes must be selected, defined and measured consis-
tently across studies of similar interventions in similar 
populations. Core outcome sets (COS), developed using 
rigorous consensus processes involving key stakeholders 
including patients and carers, comprise outcomes 
perceived as fundamental to measure in all trials related 
to a specific and defined area of interest (such as a 
disease, condition or intervention).21 22 Although the 
importance and value of COS for standardising outcomes 
and measurement across trials is increasingly recognised, 
in general, they are still in their infancy and as yet have 
not been developed for trials of interventions to prevent 
or treat delirium. Therefore, we aim to develop inter-
national consensus on two COS appropriate for trials 
of interventions designed to (1) prevent or (2) treat 
delirium, irrespective of study population. We also aim to 
identify additional core outcomes specific to four patient 
groups: the critically ill, patients requiring hospitalisation 
in an acute care setting, palliative care and older adults 
living in residential care or the community.
Scope of core outcome set development
The scope of our COS will include our four patient popu-
lations of interest, considered at high risk of developing 
delirium.3 5 23 24 These include (1) critically ill adults 
and children (medical, surgical and trauma) receiving 
care in high-acuity settings, including intensive care and 
high dependency units; (2) non-critically ill adults and 
children hospitalised in acute care settings, including 
surgical (all surgeries) and medical patients and patients 
presenting to an emergency department; (3) adults and 
children receiving palliative care, either in a hospital, 
hospice or community setting and (4) older adults (≥65 
years) living in nursing or residential care homes or living 
in their own homes and defined as at risk of delirium by 
study authors. We recognise that certain subpopulations 
such as children and older adults with dementia span-
ning these patient populations may need a distinct COS 
or outcomes for substitution within a COS. This decision 
will be made following identification and mapping of 
outcomes during our systematic review and from inter-
views with patients/family.
METhodS
We will use methods outlined in the Outcome Measures 
in Rheumatology (OMERACT) handbook25 and those 
endorsed by the Core Outcome Measures in Effectiveness 
Trials (COMET) initiative.26 Our study steering group 
will comprise two experts with clinical and/or research 
expertise in delirium and a patient/family representative 
for each of our four patient populations. We will use the 
COMET Checklist for Public Research Partners and the 
COS Study Developers Involved in Designing a COS study 
checklist27 to guide and optimise our engagement with 
patients/family around the COS design and conduct.
Information sources
We will conduct (1) a systematic review of outcomes and 
measures reported in published and ongoing trials of 
interventions to prevent or treat delirium (1980 onwards) 
and (2) a qualitative study comprising one-on-one inter-
views with patient survivors, family members and patient 
advocacy groups to identify outcomes important to 
patients and families that have experienced delirium.
Systematic review
Search strategy and data sources
We will develop an electronic search strategy through an 
iterative process informed by an experienced medical 
information specialist. We will search the following elec-
tronic databases, adjusting vocabulary and syntax for each, 
from 1980 to present: Ovid MEDLINE, Ovid MEDLINE 
In-Process & Other Non-Indexed Citations, CINAHL, 
Embase Classic+Embase, PsychINFO and Web of Science 
(online supplementary file 1). To avoid limiting the scope 
of outcomes identified, we will not apply a study design 
filter. We will limit inclusion to studies published in 
English. A second librarian will review the search strategy 
prior to execution using the Peer Review for Electronic 
Search Strategies template.28 29 We will search for relevant 
systematic reviews in the Cochrane Library, PROSPERO, 
and Joanna Briggs and unpublished studies and ongoing 
trials on the International Clinical Trials Registry Plat-
form (http:// apps. who. int/ trialsearch).
Study selection
Two investigators will independently screen titles and 
abstracts for eligible studies. Inclusion criteria include 
(1) one of the four patient groups of interest; (2) phar-
macological and non-pharmacological interventions for 
delirium prevention, treatment or both; (3) compared 
with usual care, other pharmacological agents or other 
non-pharmacological interventions and (4) randomised 
(individual, cluster and cross-over randomisation), 
quasi-randomised and non-randomised intervention 
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studies. If we identify <5 intervention studies in any of the 
four patient groups, we will expand our inclusion criteria 
to include observational studies with a control group. We 
will examine full-text publications of potentially relevant 
articles for eligibility. We will screen the reference lists 
of eligible studies and systematic reviews for additional 
eligible studies for inclusion. We will resolve disagree-
ments through discussion; if unable to achieve consensus, 
we will refer to an independent arbiter from among the 
study team.
Data extraction 
Two investigators will independently extract data from 
eligible studies on publication date, design, participant 
characteristics, study objectives, intervention, compar-
ator, outcomes, their definition and measures used to 
document outcomes.
Quality assessment
Two investigators will assess independently the risk of 
bias using the Cochrane Risk of Bias tool for randomised 
and quasi-randomised studies and the Scottish Intercolle-
giate Guidelines Network checklists for non-randomised 
studies.30 Two investigators will assess independently 
the quality of describing and reporting outcomes using 
the 6-point MOMENT scoring system with a score of ≥4 
representing high-quality outcome reporting.31 The six 
elements (each scored as 1 point) include (1) Was the 
primary outcome stated? (2) Was the primary outcome 
clearly defined so that another researcher would be able 
to reproduce its measurement? (3) Were the secondary 
outcomes clearly stated? (4) Were the secondary outcomes 
clearly defined? (5) Do the authors explain the choice 
of outcomes they have selected? and (6) Were methods 
used to enhance quality of outcome measurement, if 
appropriate? We will resolve disagreements though 
discussion; if unable to achieve consensus, we will refer to 
an independent arbiter.
Data synthesis
We will generate tables of outcomes, their descriptions 
and measures. We will tabulate the proportion of included 
studies that report on each outcome and rank order the 
outcomes accordingly. We will calculate the frequency of 
the following scenarios: (1) outcomes reported with the 
same title and definition, (2) outcomes reported with 
the same title but different definition and (3) outcomes 
reported with different titles but the same definition. We 
will then map outcomes to the OMERACT domains.25 
We will use the outcome matrix as recommended by the 
Outcome Reporting for Brief Intervention Trials (ORBIT) 
project to organise outcomes.32 Steering group members 
will review the outcome list to identify those with similar 
wording or meaning to be reduced to a single outcome 
for the purposes of the Delphi round 1 questionnaire.
Qualitative study
We will conduct patient and family member interviews 
as evidence indicates that they may hold different views 
about which outcomes are of relevance compared with 
healthcare professionals.33
Study sample
We will use purposive34 and maximum variation sampling35 
to identify patient and family participants with the char-
acteristics shown in table 1 (minimum of one representa-
tive of each characteristic) for each patient group. For the 
patient groups representing high-acuity settings, acute 
care settings and palliative care, we will also target parents 
and where possible children who have experienced 
Table 1 Stakeholder sampling characteristics
Stakeholder group Characteristic
Patients/family members*
Age, years (≤65 and >65)
Sex (male and female)
Partner status (has partner and no partner)
Country of residence (North America, Europe/UK, Australasia and other)
Expert clinicians†
Profession (physician, nurse and allied health professionals)
Years of relevant clinical experience (<5, 5–10 and >10)
Country of residence (North America, Europe/UK, Australasia and other)
Trialists/researchers‡
Stage of research career (early: <5 years, mid: 5–15 years and senior >15 years)
Country of residence (North America, Europe/UK, Australasia and other)
*Patients who survived delirium within the last 18 months and family members who had direct contact with patients while experiencing 
delirium within the last 18 months irrespective of survival, that is, we will interview family members of patients who did and did not survive the 
intensive care unit.
†Physicians, nurses and allied health professionals who do not meet the criteria of a trialist.
‡Authors of published (over the last 10 years) or ongoing clinical trials evaluating interventions aimed at preventing or treating delirium.
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delirium. For pragmatic reasons related to resource avail-
ability, we will only be able to recruit participants fluent 
in English. We will recruit a sample of 15–20 participants 
for each patient group which should to be sufficient to 
achieve saturation.36 We will adjust our sample size using 
a stopping criterion of three consecutive interviews with 
no additional material to terminate data collection.
Data collection
An experienced qualitative researcher will conduct semi-
structured telephone interviews enabling representation 
across a wide geographical area. Following clarifica-
tion of what a study outcome is and the importance of 
COS, patient/family members will be asked to suggest 
the outcomes of relevance to them when considering 
their experience of delirium, why these outcomes are 
important and to identify which outcomes they would 
consider core and why. All interviews will be audio-re-
corded and transcribed for analysis.
Data analysis
The experienced qualitative researcher and study inves-
tigator will independently examine interview transcripts 
using content analysis methods.37 Outcomes that do not 
duplicate those identified from the systematic review will 
be categorised into domains and noted as only being 
identified by patients/family. Discussion with another 
investigator and the patient/family representative on the 
steering committee will confirm outcomes are of rele-
vance, not duplicative and allocated to the appropriate 
domain.38
delphi consensus building exercise
Participants, recruitment and sample size
We will use the eligibility criteria and sampling strategy 
shown in table 1 ensuring a minimum of two participants 
from each stakeholder group (patients/family members, 
expert clinicians and trialists/researchers) representing 
each of the demographic variables and categories within 
those variables. If required, we will modify our recruit-
ment advertising to target individuals meeting our demo-
graphic targets. For the patient groups representing 
high-acuity settings, acute care settings and palliative 
care, we will also aim to have a minimum of five partic-
ipants representing paediatrics in each group if deemed 
appropriate to combine in the same COS development 
process following our systematic review work. We will aim 
to maintain a minimum of 20 participants representing 
each stakeholder group (total of 60 participants) for each 
patient population (total of 240 participants) throughout 
Delphi rounds (R). Based on an estimated attrition of 
30% across rounds, we will target recruitment of 310 
participants. A sample size of 240 participants will give us 
80% power with two-sided test at α=5% to detect a differ-
ence of 1.0–1.5 points between rounds on the Grading 
of Recommendations Assessment, Development and 
Evaluations (GRADE) scale39 (range 1–9) by feedback 
groups when SDs for change vary between 1.4 and 4.1. A 
priori we anticipate there may be differences in responses 
provided by patients and family members compared with 
those provided by clinicians and researchers. We will test 
for interaction and if significant, examine each group 
separately.
We will recruit expert clinicians using recruitment 
flyers sent through membership lists of the European, 
American and Australasian Delirium Associations/Soci-
eties as well as professional societies of clinicians treating 
our patient groups. We will continue to enrol participants 
until our sample size and maximum variation targets are 
met. We will send personalised recruitment emails to all 
trialists/researchers identified via our systematic review. 
As patient/family recruitment may possess challenges, 
we will use a multimodal strategy including contact with 
relevant patient/family support/advocacy groups/char-
ities and generic organisations such as the James Lind 
Alliance and COMET, use of social media including 
twitter and patient-focused Facebook pages, adver-
tisements placed on public and patient involvement 
websites, hospital patient engagement and patient and 
public involvement groups, snowballing techniques and 
personal contacts.
Round 1
We will include all outcomes identified through our 
systematic review and patient/family interviews. We will 
describe outcomes in lay terms, with medical terms in 
brackets, to improve comprehensibility by all. We will seek 
advice from our patient/family steering group members 
for lay descriptions. To introduce the Delphi, we will 
provide plain language summaries developed by COMET. 
We will programme the Delphi using the online e-man-
agement system such as the one developed by COMET. 
Prior to execution, we will pilot the questionnaire with 
eight individuals (patients, family members, healthcare 
professionals and trialists) to assess face validity, under-
standing and acceptability.
We will provide participants with outcomes identified 
through systematic review and interviews common to all 
four patient groups. In addition, we will provide those 
outcomes specific to one of our four patient groups only 
to participant representatives of that group. We will ask 
participants to score each outcome using the GRADE 
scale39 which ranges from 1 to 9 (1 to 3=not important 
for inclusion, 4 to 6=important but not critical and 7 to 
9=critical for inclusion). We selected this scoring system 
to facilitate maximum discrimination between question-
naire items as noted by COMET40 41 and to enable testing 
of our methodological hypotheses. To avoid presenta-
tion bias, we will randomise outcome presentation for 
each participant. We will provide the opportunity to add 
additional outcomes. We will send three email comple-
tion reminders at 2-week intervals. We will collect demo-
graphic information to describe our study sample and 
to provide each respondent with a unique identifier, 
enabling personalised reminders for completion of subse-
quent rounds.
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We will examine data distribution of importance scores 
attributed to each outcome and calculate the mean and 
SD. We will determine the proportion of participants 
rating each outcome as 7–9, 4–6 and 1–3. To reduce 
participant burden, we will retain for R2 those items 
scored between 7 and 9 (critical importance) by ≥50% 
and between 1 and 3 (not important) by <15% of respon-
dents. We will apply these criteria separately for patient 
group.
Round 2
The steering group will review any additional outcomes 
provided in R1 to determine whether they represent new 
outcomes for inclusion and to ensure wording is under-
standable by all participants. We will provide partici-
pants with their own R1 response, summarised responses 
according to their patient population group, summarised 
responses of patient/family member participants (also 
according to patient group), and ask them to rescore the 
importance of each outcome. We will provide any new 
outcomes from R1 for scoring on the 1–9 importance 
scale. As with R1, we will send three email completion 
reminders at 2-week intervals.
If new outcomes are identified in R1, we will conduct 
a third round comprising only these items to enable 
two rounds of importance scoring. Items to be brought 
forward to the consensus meeting will be those scored 
between 7 and 9 by ≥70% of participants and between 1 
and 3 by <15% of participants. We will identify items sepa-
rately for (1) patients/family and (2) healthcare profes-
sionals and researchers combined.
In the event of significant attrition (defined as loss 
of more than 30% of participants within a stakeholder 
group) between rounds 1 and 2, we will engage in addi-
tional recruitment for Round 2. A priori we anticipate 
this may be particularly problematic for patients in the 
palliative group.
nested methodological studies
We will conduct nested methodological studies to:
1. Determine whether Delphi feedback provided as 
the proportion of participants scoring the outcome 
between 7 and 9 (indicating critical for inclusion) as 
opposed to mean scores influences subsequent scores, 
magnitude of change, items retained and level of 
agreement (overall and by patient population group).
2. Qualitatively explore the process of patient/family en-
gagement and participation throughout COS devel-
opment to determine barriers and facilitators as well 
as modification of our processes if needed.
3. Determine whether Delphi versus nominal group 
technique influences which measures are retained for 
outcomes included in the COS.
delphi feedback
Randomisation and allocation
We will randomise (1:1 stratified by patient population 
group) using a computer-generated schedule developed 
by the study statistician. We will generate a questionnaire 
for each Delphi participant using this allocation schedule. 
Participants will be randomised to receive feedback as 
either the proportion of participants scoring the outcome 
as critical (for their patient population group) or patient 
population group mean response (figure 1).
Statistical analysis
We will analyse differences between feedback groups in 
terms of: (1) subsequent scores and magnitude of opinion 
change, (2) items retained at Delphi end and (3) level of 
agreement between patient population groups. We will 
calculate the percentage of items for which a participant 
changed their score between rounds and the mean abso-
lute change in score (ignoring direction of change). We 
will compare results according to randomisation group 
using an independent t-test overall and by patient popu-
lation group. For each outcome, we will use linear regres-
sion to compare R2 scores between feedback groups and 
among patient population groups, adjusting for R1 scores 
and testing for the interaction between feedback groups 
and patient populations.
To ascertain feedback group differences for items 
retained, we will create contingency tables, for each feed-
back group, to categorise the number of items retained 
by (1) both feedback groups, (2) critical response feed-
back group only, (3) mean feedback group only and (4) 
neither. We will determine the percentage of items for 
which there was agreement to retain and percentage of 
discordant items retained by only one feedback group. To 
ascertain differences between feedback groups in terms 
of the level of agreement of items retained across patient 
population groups, we will generate contingency tables 
categorising number of items retained by (1) all, (2) one 
group only, (3) two groups only, (4) three groups only 
and (5) none. We will calculate the percentage agree-
ment and percentage of discordant items.
To explore the impact of feedback on consensus 
between patient population groups, we will transform the 
unit of analysis to be the questionnaire item (outcome), 
with each observation an aggregate statistic. We will use 
linear regression to determine, for each outcome and for 
each feedback group, the absolute difference (ignoring 
direction) in mean R2 scores, adjusting for the partici-
pant’s R1 score. We will compare absolute mean differ-
ences between patient population groups across outcomes 
between the two feedback groups using a paired t-test. 
Finally, we will compare responses irrespective of patient 
population groups within each randomisation arm, calcu-
late the SD for each outcome separately for R1 and R2 
and calculate the reduction in each outcome’s variability 
between rounds. We will compare mean reductions in 
SD across all outcomes between feedback groups using a 
paired t-test.
Given the anticipated number of statistical tests, we 
expect 5% to result in a p-value ≤0.05 by chance; there-
fore, we will examine the percentage of tests with p≤0.05 
in relation to this expected percentage.
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outcome consensus meeting
We will hold consensus meetings to determine the 
outcomes for inclusion in the two COS’s; prevention and/
or treatment of delirium irrespective of patient popula-
tion. We will identify additional outcomes for inclusion in 
COS specific to our four patient populations. We will aim 
to be as representative of all stakeholders as possible42 
as we anticipate there may be differences between 
stakeholder groups in the priority given to outcomes. 
To ensure we have meaningful input across participant 
groups, we will invite Delphi participants to attend the 
meeting. Owing to the large size of our Delphi panel, we 
will randomly select eight participants to represent each 
of the stakeholder groups; two representing each patient 
population group.
We will provide the consensus panel with outcomes 
established as critical using either method of feedback 
for inclusion via the Delphi across all four patient groups. 
We will use a modified nominal group technique to work 
towards consensus that includes small and whole group 
discussion and ranking. Ranking will be discussed with the 
aim of agreeing on the top four or five outcomes across 
all patients and the top one to two specific to each patient 
population. To ensure there is no duplication in the final 
proposed set, each outcome will be discussed to ensure it 
relates to a distinct construct. If required, we may hold an 
additional or stand-alone consensus meeting for patients 
and family members to enable facilitation of their under-
standing and thus informed voting on outcomes for the 
COS.
Figure 1 Flow of core outcome set development. *We will conduct a third Delphi round if additional outcomes are identiied by 
participants in round 1.
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Process evaluation of patient/family participant engagement
We will conduct a process evaluation of patient/family 
participant engagement and participation throughout 
COS development.
Participants
We will recruit participants to take part in semistructured 
interviews to determine barriers and facilitators to partici-
pation as well as recommendations for improvement strat-
egies to inform future COS development. We will recruit 
15–20 participants. Interviews will be audio-recorded and 
transcribed verbatim.
Analysis
We will analyse interview transcripts using content anal-
ysis43–46 employing an inductive, four-step content analysis 
process.47 An experienced qualitative researcher and an 
investigator will independently identify, code and catego-
rise important meanings and predominant themes from 
the text. Following an immersive reading of the tran-
scripts, initial patterns and recurring categories will be 
identified by relevant highlighting sections. The second 
step will seek similarities and differences between partici-
pant accounts. Third and fourth steps involve creation of 
codes and their application over the volume of interviews, 
respectively. The larger team will be involved in in-depth 
reading of the coding to ensure credibility. NVivo 10 soft-
ware will be used for all facets of the analysis.
Instruments to measure outcomes
During our systematic review, we will also extract measures 
for outcomes reported in studies meeting our inclusion 
criteria. We will assess the measurement and psycho-
metric properties of measures of the outcomes selected 
for our two COS (prevention and treatment) using the 
COnsensus-based Standards for the selection of health 
Measurement INstruments (COSMIN) checklist.48
Participants
We will invite all Delphi participants involved in the estab-
lishment of the COS to participate in a second Delphi 
to establish measures for these outcomes. We will recruit 
additional participants if required due to attrition. We 
will recruit an additional 24 participants to take part in a 
separate consensus building exercise using only a modi-
fied nominal group technique to address the following 
hypothesis: measures selected for the COS are influenced 
by the method used for consensus building (Delphi versus 
nominal group technique).
Procedures
We will use the same Delphi methods as described above 
to establish one set of measures each for the two COSs 
(prevention and treatment) including the same nested 
study design of randomisation to two feedback methods 
(Delphi group). We will provide ‘measure cards’ 
providing standardised descriptions of the measures, 
psychometric properties and feasibility of use (ie, time to 
complete and number of items) in language understand-
able to all participants. We will use the same nominal 
group technique methods as described for the COS 
consensus meetings to establish a second set of measures 
(nominal group technique group). We will provide to the 
same description of the measures and their psychometric 
properties as provided to the Delphi method group. 
In addition, we will invite a psychometrician, clinicians 
and/or researchers with familiarity with the measures 
to the nominal group technique group, thus enabling 
informed discussion.
Statistical analysis
We will perform the same statistical analyses as described 
for the COS Delphi to determine differences related to 
consensus group method. To ascertain differences in 
terms of measures retained between consensus group 
methods, we will create contingency tables to categorise 
number of items retained on completion by (1) both 
Delphi and nominal group technique groups, (2) Delphi 
group only, (3) nominal group technique only and (4) 
neither. We will determine the percentage of items for 
which there was agreement along with the percentage 
of discordant items, retained by one consensus group 
method but not the other.
Final consensus
We will hold a final steering group meeting to review the 
findings of the consensus building exercises. Depending 
on the number of measures rated as critical to include, we 
will hold a second consensus meeting using the methods 
described above to guide final decisions (see table 2 for 
study timeline).
Table 2 Study timeline
Key project milestones Start date End date
Systematic review May 2017 February 2018
Patient and family member interviews October 2017 February 2018
Delphi consensus and nested methodological study April 2018 March 2019
Consensus meeting June 2019 June 2019
Process evaluation patient/family interviews February 2018 March 2020
Consensus on measures September 2019 March 2020
Knowledge translation/dissemination June 2019 onwards
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Open Access 
EThICS And dISSEMInATIon
We have received research ethics board approval from 
the University of Toronto (no 34296) and will seek others 
as required by local governance. We will obtain written 
consent from participants in interviews and consensus 
meetings. Participation in Delphi rounds will be consid-
ered indicative of consent. Consent will emphasise the 
voluntary nature of participation and anonymity.
Knowledge users within our investigator team and the 
support of three international Delirium Societies (Amer-
ican, Australasian and European) will be instrumental in 
dissemination of the COSs and subsequent uptake. We will 
provide a one page summary (clinicians/researchers and 
in lay language for patients and families) to these Soci-
eties for distribution among their networks and engage 
with them to seek additional opportunities to present 
our findings (educational seminars/workshops). We 
will disseminate our findings through peer-reviewed and 
open access publications and presentations at interna-
tional conferences purposefully selected to reach a wide 
range of knowledge users taking into account geograph-
ical locations. We will engage with journal editors and 
funding agencies to promote awareness of our COSs.
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